Curigin Inc.
www.curigin.co.krAt Curigin, we are developing innovative therapies using our novel bi-specific shRNA technology to simultaneously knockdown two different disease causing pathways. Our lead pipelines target cancer pathways such as mTOR and STAT3 and deliver our bi-specific shRNA through an oncolytic virus genetically engineered to exclusively target and replicate in cancer cells.
Read more
At Curigin, we are developing innovative therapies using our novel bi-specific shRNA technology to simultaneously knockdown two different disease causing pathways. Our lead pipelines target cancer pathways such as mTOR and STAT3 and deliver our bi-specific shRNA through an oncolytic virus genetically engineered to exclusively target and replicate in cancer cells.
Read more
Employees statistics
View all employeesPotential Decision Makers
Business Development Manager
Email ****** @****.comPhone (***) ****-****
Technologies
(6)
Reach decision makers at Curigin Inc.
Free credits every month!
Curigin Inc. FAQ
Seoul, South Korea
Biotechnology Research
